ArticleJournal of King Saud University. Science2022
Unsymmetrical aromatic disulfides as SARS-CoV-2 Mpro inhibitors: Molecular docking, molecular dynamics, and ADME scoring investigations.
Article in Journal of King Saud University. Science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- MERS-Mpro Predictor: A Machine Learning-Based Tool for Rapid Screening of Potential MERS-CoV Main Protease Inhibitors.International journal of molecular sciences · 2026Article
- Computational discovery of marine natural phytochemicals as novel SIRT7 inhibitors for cancer treatment.Journal, genetic engineering & biotechnology · 2026Article
- Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.PloS one · 2026Article
- Peptides From Adzuki Bean and Soybean Improved Insulin-AKT Signaling-Related Pathways in Healthy and Insulin-Resistant States in Human Liver Cells.Molecular nutrition & food research · 2025Article
- Identification of potent inhibitors of potential VEGFR2: a graph neural network-based virtual screening andJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Eco-friendly synthesis of novel pyrazole derivatives and their anticancer and CDK2 inhibitory activities.RSC advances · 2025Article
- In vitro antimicrobial, anticancer evaluation, and in silico studies of mannopyranoside analogs against bacterial and fungal proteins: Acylation leads to improved antimicrobial activity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Ligand based-design of potential schistosomiasis inhibitors through QSAR, homology modeling, molecular dynamics, pharmacokinetics, and DFT studies.Journal of Taibah University Medical Sciences · 2024Article
- Identification of bioactive compounds ofHeliyon · 2024Article
- Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer.Frontiers in chemistry · 2024Article
- Article
- Molecular Docking and ADME-TOX Profiling ofAdvances in respiratory medicine · 2023Article
- Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors.International journal of molecular sciences · 2023Review
- Article
- Insight into the Interaction Mechanism of HSA with Aztreonam: A Multispectroscopic and Computational Approach.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 pandemic caused by very severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) agent is an ongoing major global health concern. The disease has caused more than 452 million affected cases and more than 6 million death worldwide. Hence, there is an urgency to search for possible medications and drug treatments. There are no approved drugs available to treat COVID-19 yet, although several vaccine candidates are already available and some of them are listed for emergency use by the world health organization (WHO). Identifying a potential drug candidate may make a significant contribution to control the expansion of COVID-19. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.